Lung cancer (Amsterdam, Netherlands), 2017-04, Vol.106, p.17-21
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes
- Ist Teil von
- Lung cancer (Amsterdam, Netherlands), 2017-04, Vol.106, p.17-21
- Ort / Verlag
- Ireland: Elsevier B.V
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights • EGFR mutations are identified concurrently with other genomic events. • The impact of concurrent mutations ( TP53 , PIK3CA , PTEN etc) on inhibitor response is unknown. • TP53 mutations commonly co-occur with EGFR mutations, and may affect clinical outcomes.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0169-5002eISSN: 1872-8332DOI: 10.1016/j.lungcan.2017.01.011Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5351777
- Format
- –
- Schlagworte
- Adenocarcinoma, Adenocarcinoma - drug therapy, Adenocarcinoma - genetics, Adenocarcinoma - pathology, Adenocarcinoma of Lung, Antineoplastic Agents - pharmacology, Carcinoma, Non-Small-Cell Lung, Class I Phosphatidylinositol 3-Kinases - genetics, Disease-Free Survival, Drug Resistance, Neoplasm, EGFR, ErbB Receptors - antagonists & inhibitors, ErbB Receptors - genetics, Erlotinib, Erlotinib Hydrochloride - pharmacology, Hematology, Oncology and Palliative Medicine, Humans, Kinase inhibitor, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - genetics, Lung Neoplasms - pathology, Mutation, Phosphatidylinositol 3-Kinases - genetics, PIK3CA, Protein Kinase Inhibitors - pharmacology, PTEN, PTEN Phosphohydrolase - genetics, Pulmonary/Respiratory, Retrospective Studies, TP53, Treatment Outcome, Tumor Suppressor Protein p53 - genetics